Glenmark USA Launches Calcium Gluconate Injection to Expand Injectable Portfolio
Glenmark Pharmaceuticals' US division has launched Calcium Gluconate Injection USP in single-dose vials and pharmacy bulk packages, expanding its injectable portfolio. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi USA's reference drug. Available in 1,000 mg, 5,000 mg, and 10,000 mg formats, the injection is used to increase calcium levels, important for bone and heart health. The US market for this drug recorded annual sales of about $69.9 million as of June 2026.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 35/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–65/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 21 Aug, 04:51 am. Other outlets followed.
- 1